header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-PUB-081110-1
Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein
Yang, T., Arslanova, D., Gu, Y., Augelli-Szafran, C., and Xia, W.
Date: 2008
Source: Molecular brain   1(1): 15 (Journal)
Registered Authors: Xia, Weiming
Keywords: none
MeSH Terms:
  • Amyloid Precursor Protein Secretases/antagonists & inhibitors*
  • Amyloid Precursor Protein Secretases/metabolism
  • Amyloid beta-Protein Precursor/metabolism*
  • Animals
  • Basic Helix-Loop-Helix Transcription Factors/genetics
  • Basic Helix-Loop-Helix Transcription Factors/metabolism
  • Dipeptides/pharmacology
  • Embryo, Nonmammalian/drug effects
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression Regulation/drug effects
  • Mutation/genetics
  • Phenotype
  • Protease Inhibitors/pharmacology*
  • Protein Structure, Tertiary
  • Receptors, Notch/antagonists & inhibitors
  • Receptors, Notch/metabolism*
  • Recombinant Proteins/metabolism
  • Signal Transduction/drug effects
  • Substrate Specificity/drug effects
  • Zebrafish/embryology
  • Zebrafish/genetics
  • Zebrafish Proteins/genetics
  • Zebrafish Proteins/metabolism
PubMed: 18983676 Full text @ Mol. Brain
FIGURES
ABSTRACT
BACKGROUND: Deposition of amyloid beta protein (Abeta) is a major pathological hallmark of Alzheimer's disease (AD). Abeta is generated from gamma-secretase cleavage of amyloid precursor protein (APP). In addition to APP, gamma-secretase also cleaves other type I integral membrane proteins, including the Notch receptor, a key molecule involved in embryonic development. RESULTS: To explore selective gamma-secretase inhibitors, a combination of five methods was used to systematically determine these inhibitors' profiles on the gamma-secretase cleavage of APP and Notch. When two potent gamma-secretase inhibitors, compound E (cpd E) and DAPT, were used in a conventional in vitro gamma-secretase activity assay, cpd E completely blocked Abeta generation from the cleavage of substrate APP C100, but only had a minor effect on Notch cleavage and NICD generation. Next, cpd E and DAPT were applied to HEK293 cells expressing a truncated Notch substrate Notch deltaE. Both cpd E and DAPT were more potent in blocking Abeta generation than NICD generation. Third, a reporter construct was created that carried the NICD targeting promoter with three Su(H) binding sequences followed by the luciferase gene. We found that the inhibition of NICD generation by cpd E and DAPT was consistent with the reduced expression of luciferase gene driven by this Notch targeting promoter. Fourth, levels of "Notch-Abeta-like" (Nbeta*) peptide derived from two previously reported chimeric APP with its transmembrane domain or the juxtamembrane portion replaced by the Notch sequence were quantified. Measurement of Nbeta* peptides by ELISA confirmed that EC50's of cpd E were much higher for Nbeta* than Abeta. Finally, the expression levels of Notch target gene her6 in cpd E or DAPT-treated zebrafish were correlated with the degree of tail curvature due to defective somitogenesis, a well characterized Notch phenotype in zebrafish. CONCLUSION: our ELISA-based quantification of Abeta and Nbeta* in combination with the test in zebrafish provides a novel approach for efficient cell-based screening and in vivo validation of APP selective gamma-secretase inhibitors.
ADDITIONAL INFORMATION